---name: liquid-biopsy-analytics-agent description: AI-powered comprehensive liquid biopsy analysis integrating ctDNA, CTCs, exosomes, and cfRNA for cancer detection, monitoring, and treatment guidance. license: MIT metadata: author: AI Group version: "1.0.0" created: "2026-01-19" compatibility:

• system: Python 3.10+ allowed-tools:
• run_shell_command
• read_file
• write_file

keywords:

• liquid-biopsy-analytics-agent
• automation
• biomedical measurable_outcome: execute task with >95% success rate. ---"

Liquid Biopsy Analytics Agent

The Liquid Biopsy Analytics Agent provides comprehensive AI-driven analysis of blood-based cancer biomarkers. It integrates circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and cell-free RNA for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and treatment response assessment.

When to Use This Skill

• For multi-cancer early detection screening from blood samples.
• To monitor minimal residual disease (MRD) after curative treatment.
• When tracking tumor evolution and resistance during therapy.
• For real-time treatment response assessment.
• To detect cancer recurrence before clinical or imaging evidence.

Core Capabilities

1. ctDNA Mutation Analysis: Variant calling, VAF tracking, and clonal evolution from cell-free DNA.

2. Methylation-Based Detection: cfDNA methylation patterns for cancer detection and tissue-of-origin identification.

3. CTC Enumeration & Analysis: AI-powered CTC detection, enumeration, and molecular characterization.

4. Multi-Modal Integration: Combines ctDNA, CTCs, and protein biomarkers with clinical/imaging data.

5. MRD Monitoring: Ultra-sensitive detection of residual disease post-treatment.

6. Response Prediction: AI models predicting treatment response from longitudinal liquid biopsy data.

Analyte Types and Applications

Analyte	Detection Method	Clinical Use
ctDNA mutations	NGS, ddPCR	Therapy selection, resistance
ctDNA methylation	WGBS, targeted	MCED, tissue of origin
ctDNA fragmentation	WGS	Cancer detection
CTCs	CellSearch, microfluidics	Prognosis, monitoring
Exosomes	Immunocapture	Biomarker cargo
cfRNA	RT-qPCR, NGS	Gene expression

Workflow

1. Input: Liquid biopsy data (ctDNA variants, methylation, CTC counts, protein markers).

2. Quality Control: Assess sample quality, input DNA amount, background noise.

3. Variant Analysis: Call mutations, calculate VAF, filter artifacts (CHIP).

4. Multi-analyte Integration: Combine biomarker signals using ML fusion.

5. Clinical Interpretation: Generate actionable insights for treatment decisions.

6. Longitudinal Tracking: Model dynamics for response assessment and recurrence detection.

7. Output: Cancer detection probability, MRD status, treatment recommendations, clonal evolution.

Example Usage

User: "Analyze longitudinal ctDNA data from this lung cancer patient to assess treatment response and detect resistance."

Agent Action:

python3 Skills/Oncology/Liquid_Biopsy_Analytics_Agent/lb_analyzer.py \
    --ctdna_variants longitudinal_ctdna.vcf \
    --timepoints week0,week4,week8,week12 \
    --tumor_markers cea_values.csv \
    --baseline_tissue baseline_tumor.maf \
    --analysis response_resistance \
    --chip_filter true \
    --output lb_report/

AI/ML Models

Multi-Cancer Early Detection (MCED):

• Methylation-based classifiers (sensitivity ~50-80% at 99% specificity)
• Multi-analyte combination models
• Tissue-of-origin prediction
• Integration with imaging and clinical risk

MRD Detection:

• Tumor-informed (personalized panels from tissue)
• Tumor-agnostic (fixed panels, methylation)
• Detection limits: 0.01% - 0.001% VAF

Response Prediction:

• Longitudinal VAF dynamics modeling
• Bayesian evolution frameworks
• Time-to-progression prediction

Clonal Hematopoiesis Filtering

Critical challenge in liquid biopsy interpretation:

Gene	Prevalence	Action
DNMT3A	30-40% of CHIP	Filter if VAF stable, no tumor context
TET2	20-30%	Filter if VAF stable
ASXL1	10-15%	Filter if VAF stable
TP53	5-10%	Context-dependent (tumor vs CHIP)
Matched WBC	Gold standard	Subtract germline/CHIP variants

Commercial Platforms (Reference)

Platform	Technology	Application
Guardant360	ctDNA NGS	Therapy selection
FoundationOne Liquid	ctDNA NGS	Comprehensive profiling
Galleri	Methylation	MCED screening
Signatera	Tumor-informed	MRD monitoring
CellSearch	CTC	FDA-cleared enumeration

Clinical Decision Points

1. Treatment Selection: Actionable mutations (EGFR, ALK, ROS1, BRAF)
2. Response Assessment: ctDNA clearance correlates with outcomes
3. Resistance Detection: Emerging resistance mutations (T790M, C797S)
4. Recurrence Monitoring: Lead time of 3-6 months over imaging

Prerequisites

• Python 3.10+
• NGS variant calling pipelines
• Methylation analysis tools
• Machine learning frameworks

Related Skills

• ctDNA_Analysis - For detailed ctDNA workflows
• Tumor_Clonal_Evolution - For evolutionary analysis
• MRD_Detection - For residual disease focus

Limitations and Considerations

• False positives: CHIP, benign tumors, inflammation
• False negatives: Low shedding tumors, early stage
• Technical variability: Pre-analytical factors critical
• Cost: Multi-analyte panels expensive

Author

AI Group - Biomedical AI Platform